Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Rapport sur les actions

Capitalisation boursière : US$9.5b

Intra-Cellular Therapies Résultats passés

Passé contrôle des critères 0/6

Intra-Cellular Therapies a connu une croissance annuelle moyenne de ses bénéfices de 5.8%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en baisse à 0.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 63.9% par an.

Informations clés

5.8%

Taux de croissance des bénéfices

15.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie6.0%
Taux de croissance des recettes63.9%
Rendement des fonds propres-7.5%
Marge nette-14.1%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

Ventilation des recettes et des dépenses

Comment Intra-Cellular Therapies gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGS:ITCI Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 24614-864710
30 Jun 24565-844450
31 Mar 24514-1114240
31 Dec 23464-1404100
30 Sep 23420-1554000
30 Jun 23366-1843830
31 Mar 23311-2283820
31 Dec 22250-2563590
30 Sep 22188-2983440
30 Jun 22138-3213260
31 Mar 22103-3042950
31 Dec 2184-2842730
30 Sep 2171-2592510
30 Jun 2156-2372330
31 Mar 2138-2322050
31 Dec 2023-2271860
30 Sep 2010-2071510
30 Jun 203-1871130
31 Mar 201-160870
31 Dec 190-148650
30 Sep 190-148510
30 Jun 190-155440
31 Mar 190-154350
31 Dec 180-155300
30 Sep 180-145270
30 Jun 180-126240
31 Mar 180-106240
31 Dec 170-98240
30 Sep 170-95250
30 Jun 170-102260
31 Mar 170-116260
31 Dec 160-116250
30 Sep 160-118240
30 Jun 160-120220
31 Mar 160-110190
31 Dec 150-105180
30 Sep 150-91150
30 Jun 150-65140
31 Mar 150-48120
31 Dec 141-31100
30 Sep 141-2490
30 Jun 142-2280
31 Mar 142-2670
31 Dec 133-2760

Des revenus de qualité: ITCI n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: ITCI n'est actuellement pas rentable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: ITCI n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 5.8% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de ITCI au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: ITCI n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 54.6% ).


Rendement des fonds propres

ROE élevé: ITCI a un retour sur capitaux propres négatif ( -7.54% ), car il n'est actuellement pas rentable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé